Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in a fireside chat and one-on-one meetings at Cantor’s 2026 Global Healthcare Conference, scheduled for Sept. 9-11, 2026, in New York. President and CEO Seth Lederman, M.D., will present on Sept. 10 from 3:55-4:25 p.m. ET, with a live webcast and replay available through the Investors section of the Tonix website.
This engagement comes at a pivotal time for Tonix, which recently received approval for TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. The company is now focused on maximizing the commercial potential of this flagship medicine while advancing a robust pipeline targeting central nervous system (CNS) and immunology indications with high unmet medical need.
The significance of Tonix’s participation in this conference lies in its ability to communicate directly with investors and industry stakeholders about the company’s strategic direction. With TONMYA as a newly approved product, Tonix is building its CNS commercial infrastructure to support not only TONMYA but also its acute migraine products, Zembrace SymTouch and Tosymra. This infrastructure is crucial for the successful launch and market penetration of TONMYA, which addresses a condition that has seen limited innovation for years.
Beyond commercialization, Tonix is actively exploring the therapeutic potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. These expansion efforts could broaden the drug’s indications, potentially increasing its market size and reinforcing the company’s position in CNS therapeutics. Additionally, the company’s pipeline includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder, and immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection.
The presentation at the Cantor conference provides a platform for Tonix to highlight these developments and articulate its vision for future growth. For investors, the conference offers insights into the company’s operational milestones, regulatory progress, and market opportunities. The live webcast and replay ensure broad accessibility, allowing stakeholders who cannot attend in person to stay informed.
Tonix’s participation also signals confidence in its pipeline and commercial execution. As the company navigates the post-approval phase for TONMYA, its ability to effectively market the product and advance additional candidates will be critical. The conference serves as a venue to address investor questions and provide updates on key initiatives, such as the ongoing Phase 2 trials and the development of TNX-1500 for transplantation, which could address significant unmet needs in organ transplantation.
In summary, Tonix’s presence at the Cantor 2026 Global Healthcare Conference is more than a routine corporate appearance; it represents a strategic opportunity to reinforce its commitment to addressing complex diseases and to showcase a pipeline that holds promise for multiple therapeutic areas. As the company continues to execute on its commercial and clinical objectives, its performance will be closely watched by investors and the medical community alike.
